"Later, lazier, and unluckier": A heuristic profile of high vulnerability is an independent predictor of uncontrolled blood pressure (the PREVIEW study)

International Journal of General Medicine

Volumn 3, Issue , 2010, Pages 163-166

  Abraham, Ivo ^a,b   Lee, Christopher ^a,b   Song, Minkyoung ^a,c   Vancayzeele, Stefaan ^d   Brié, Heidi ^d   Hermans, Christine ^d   van der Niepen, Patricia ^e   MacDonald, Karen ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b Matrix45 ^*  (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^e Novartis Pharma SA NV   (Belgium)

Author keywords

Heuristics; Hypertension; Profiling; Risk; Vulnerability

Indexed keywords

ANTIHYPERTENSIVE AGENT; VALSARTAN;

ARTICLE; BLOOD PRESSURE REGULATION; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PATIENT CODING; PREDICTIVE VALIDITY; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; VALIDATION PROCESS;

EID: 79956062408     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/ijgm.s11638     Document Type: Article

References (16)

1. D'Agostino RBS, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180-187.
2. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.
3. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. New Engl J Med. 1998;339: 1957-1963.
4. Fagard RH, Van den Enden M, Leeman M, Warling X. Survey on treatment of hypertension and implementation of World Health Organization/ International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens. 2002;20:1297-1302.
5. Van der Niepen P, Giot C, van de Borne P. Prevalence of isolated uncontrolled systolic blood pressure among treated hypertensive patients in primary care in Belgium. Results of the I-inSYST survey. J Hypertens. 2008;26:2057-2063.
6. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69-75.
7. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 2003 March 1. J Hypertens. 2003;21:1055-1076.
8. Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol. 2000;85:251-255.
9. Van der Niepen P, Woestenburg A, Brié H, et al. Effectiveness vs efficacy of valsartan for treatment of hypertension: patient profiling and hierarchical modeling of determinants and outcomes. Ann Pharmacother. 2009;43:849-861.
10. Tan PN, Steinbach M, Kumar V. Data Mining. Boston, MA: Addison-Wesley; 2005.
11. Aldenderfer MS, Blashfield RK. Cluster Analysis. Thousand Oaks, CA: Sage; 1984.
12. Everitt BS, Landau B, Leese M. Cluster analysis. 2001. 4th ed. New York: Oxford University Press.
13. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC-7 report. J Am Med Assoc. 2003;289:2560-2572.
14. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
15. Kleinbaum DG, Klein M. Logistic regression. 2005. 2nd ed. New York, NY: Springer-Verlag.
16. Laragh JH. Abstract, closing summary, and table of contents for Laragh's 25 lessons in pathophysiology and 12 clinical pearls for treating hypertension. Am J Hypertens. 2001;14:1173-1174.